Publications

A list of our select publications is provided below:

Manuscripts

  1. Frech FH, Qian C, Gore M, Zhang Q. Cost implications of early treatment initiation among patients with newly diagnosed fibromyalgia. Am J Pharm Benefits. 2017;9(6):200-207.
  2. Gore M, Finnerup NB, Sadosky A, Tai K-S, Cappelleri JC, Mardekian J, Rice CG, Nieshoff E. Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin. Spinal Cord. 2013;51:126-133.
  3. Gore M, Sadosky A, Leslie D, Tai K-S, Emery P. Therapy switching, augmentation and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract. 2012;12(6):457-468.
  4. Gore M, Tai K-S, Sadosky A, Leslie D, Stacey B. Use and Costs of Prescription Medications and Alternative Treatments in Patients with Osteoarthritis and Chronic Low Back Pain in Community Based Settings. Pain Pract. 2012;12(7):550-60.
  5. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ. 2012;15(1):32-44.
  6. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15(1):19-31.
  7. Gore M, Tai Kei-Sing, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ. 2011;14:497-507.
  8. Gore M, Zlateva G, Tai Kei-Sing, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11(2):167-179.
  9. Gore M, Tai Kei-Sing, Zlateva G, Chandran AB, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011;11(6):528-39.
  10. Gore M, Sadosky A, Leslie D, Tai K-S, Seleznick M. Patterns of Therapy Switching, Augmentation and Discontinuation After Initiation of Treatment with Select Medications in Patients with Osteoarthritis. Clin Ther. 2011;33(12):1914-31.
  11. Gore M, Sadosky AB, Stacey B, Tai KS, Leslie D. The Burden of Chronic Low Back Pain: Clinical Comorbidities, Treatment Patterns, and Healthcare Costs in Usual Care Settings. Spine. Published online December 3, 2011.
  12. Gore M, Sadosky A, Zlateva G, Clauw DJ. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care. 2010;16:S144-S153.
  13. Gore M, Sadosky A, Zlateva G, Clauw DJ. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9(5):363–374.
  14. Gore M, Sadosky A, Leslie DL, Heck Sheehan A. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: A study using the U.K. and Germany Mediplus databases. Pain Pract. 2008;8(4):253–262.
  15. Gore M, Sadosky A, Tai K-S, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther. 2007;25(8):1655-1670.
  16. Gore M, Dukes E, Rowbotham DJ, Tai KS, Leslie DL. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eu J Pain. 2007; 11(6):652-64.
  17. Gore M, Dukes EM, Rowbotham DJ, Tai KS, Leslie DL. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract. 2006;6(4):265-72.
  18. Gore M, Brandenburg N, Hoffman D, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy (DPN): The patients’ perspectives. J Pain. 2006;7(12):892-900.
  19. Zelman D, Brandenburg N, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22(8):681-685.
  20. Gore M, Brandenburg N, Dukes E, Hoffman DL, Tai K-S. Pain Severity in Diabetic Peripheral Neuropathy (DPN) is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. J Pain Symptom Manage. 2005;30(4):374-385.
  21. Zelman DC, Gore M, Dukes E, Tai K, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for Painful Diabetic Peripheral Neuropathy. J Vasc Nurs. 2005;23(3):97-104.
  22. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain. 2005;115(1-2):29-36.
  23. Zelman DC, Gore M, Dukes E, Tai K, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for Painful Diabetic Peripheral Neuropathy. J Pain Symptom Manage. 2005;29(4):401-410.
  24. Lennox RD, Fowler I, Gore M, Jones MKC, Pethick N, O’Dowd L. Psychometric validation of a patient-reported sensory perception and preference instrument: The sensory perceptions questionnaire. Advances in Therapy. 2004;21(3):162-172.
  25. Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP. The Cost-effectiveness of Tamoxifen in the Prevention of Breast Cancer. Am J Manag Care. 1999;5(6):S389-406.
  26. Pater J, Osoba D, Zee B, Lofters W, Gore M, Dempsey E, Palmer M, Chin C. Effects of Altering the Time of Administration and the Timeframe on EORTC QLQ-C30 Quality of Life Assessments in a large Anti-emetic Trial. Qual Life Res. 1998;7(3):273-278.
  27. Namjoshi M, Gore M. Quality of Life Assessments in HIV-related diseases: A review of current methodologies. Drug Information Journal. 1997;31:1407-1439.
  28. Gore M, Hansen S, Miller L. Developing a Regulatory Strategy for Monoclonal Antibodies. Drug Information Journal. 1996;30(1):251-267.
  29. Gore M, Thomas J. Store Image as a Predictor of Store Patronage for Nonprescription Medication Purchases: A Multi-attribute Model Approach. J Pharm Mark Manage. 1996;10(1):45-68.
  30. Gore M, Thomas J. Perceived Importance and Availability of Nonprescription Informational Services in Pharmacies and Alternative Outlets: Implications for a Third Class of Drugs. Journal of Social and Administrative Pharmacy. 1995;12(2):86-99.

Posters & Oral Presentations

  1. Frech F, Qian C, Gore M, Zhang Q. Treatment initiation timing and healthcare costs in newly diagnosed patients with fibromyalgia. Abstract publication in Neurology April 5, 2016, Vol 86, no. 16, Supplement P6.276. American Academy of Neurology 2016 Annual Meeting, Vancouver, April 2016.
  2. Lang K, Gore M, Mehta S, Zhang Q, Graham C, Thompson D, Frech F. Clinical characteristics, pain assessment, and treatment patterns among fibromyalgia patients: An analysis of linked electronic medical records and administrative claims data. Academy of Managed Care Pharmacy Nexus Conference, Orlando, October 2015.
  3. Gore M, Finnerup NB, Sadosky A, Tai K-S, Nieshoff E. Initial Use of Pregabalin in Patients with Neuropathic Pain Following Spinal Cord Injury. ASCIP Annual Meeting 2012.
  4. Gore M, Sadosky A, Leslie DL, Tai K-S, Emery P. Therapy Switching, Augmentation and Discontinuation in Patients with Chronic Low Back Pain in the United Kingdom. Eur J Pain. 2011; Supplement 5: P42.
  5. Chandran A, Leslie DL, Tai K-S, Zlateva G, Gore M. Clinical comorbidities, treatment patterns and healthcare costs among patients with Fibromyalgia newly prescribed pregabalin or duloxetine in usual care. APS 30th Annual Scientific Meeting 2011.
  6. Chandran A, Zlateva G, Leslie DL, Tai K-S, Gore M. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. APS 30th Annual Scientific Meeting 2011.
  7. Sadosky A, Gore M, Leslie DL, Tai K-S, Seleznick M. Patterns of therapy switching, augmenting and discontinuation after initiation of treatment with select medications in patients with osteoarthritis: a retrospective claims database analysis. APS 30th Annual Scientific Meeting 2011.
  8. Gore M, Sadosky A, Leslie D, Tai K, Emery P. Patterns of Therapy Switching, Augmentation and Discontinuation After Initiation of Treatment with Select Medications in Patients with OA Using the United Kingdom THIN Database. OARSI Annual Meeting 2011.
  9. Gore M, Zlateva G, Chandran A, Tai K, Leslie D. Painful Diabetic Neuropathy Newly Prescribed Pregabalin or Gabapentin in Usual Care Settings. AMCP’s 23rd Annual Meeting & Showcase 2011.
  10. Gore M, Sadosky AB, Tai KS, Leslie D, Stacey B. Clinical comorbidities, pain-related pharmacotherapy, and direct medical costs of patients with osteoarthritis in clinical practice. OARSI Annual Meeting 2010.
  11. Gore M, Sadosky AB, Leslie D, Stacey B. Clinical comorbidities, treatment patterns, and healthcare costs of patients with chronic low back pain in usual care settings in the United States. ASRA Annual Meeting 2010.
  12. Gore M; Zlateva G, Chandran A, Douglas L. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. ACR Annual Meeting 2010.
  13. Gore M; Zlateva G, Chandran A, Tai KS, Douglas L. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or duloxetine.  AAPM Annual Meeting 2010.
  14. Gore M, Zlateva G, Chandran A, Tai KS, Leslie Treatment patterns and costs of diabetic neuropathy. 21st Annual Clinical Meeting at American Academy of Pain Management. September 21 -24, 2010.
  15. Gore M, Sadosky A, Zlateva G, Clauw DJ. Patterns of pain-related pharmacotherapy and healthcare resource use among elderly patients with fibromyalgia prescribed pregabalin. ACR Congress 2009.
  16. Gore M, Sadosky A, Zlateva G. Appropriate medication use in elderly fibromyalgia patients. AAPM Congress 2009.
  17. Gore M, Dukes EM, Sadosky A, Stacey B. Clinical characteristics and pain management in patients with diabetic neuropathy prescribed select neuropathic pain-related medications. WCP Congress 2008.
  18. Gore M, Brandenburg N, Tai K-S, Stacey B. Initial use of pregabalin and gabapentin in patients with diabetic neuropathy and postherpetic neuralgia: achieving the minimally effective dose. J Pain.  2007;8(4), Supplement 1: S31. Abstract #722.
  19. Gore M, Sadosky A, Dukes EM, Tai K-S, Leslie D, Heck-Sheehan A. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: A study using the UK and Germany Mediplus Databases.  NeuPSig Congress 2007.
  20. Sadosky A, Gore M, Rowbotham D, Tai K, Dukes E. Clinical comorbidities and treatment patterns in patients with pure vs mixed neuropathic pain in general practice in the United Kingdom. Ninth International Conference on the Mechanisms and Treatment of Neuropathic Pain. November 2-4, 2006.
  21. Gore M, Brandenburg N, Tai K. Racial and ethnic disparities in individuals with painful diabetic peripheral neuropathy (DPN). Supplement to Diabetes. June 2006.
  22. Gore M, Brandenburg N, Tai KS, Leslie D. Cluster analysis of psychosocial and medication use profiles of patients with painful diabetic peripheral neuropathy (DPN). J Pain. 2006b;7(4)Suppl 2:S2.
  23. Gore M, Dukes E, Rowbotham D, Sadosky A, Tai K, Leslie D. Use of potentially inappropriate pain-related medications in elderly patients with diabetic neuropathy in general practice settings. Journal of Neurology. 2006;253(Suppl 2):II/109, P431.
  24. Leslie D, Sadosky A, Rowbotham D, Dukes E, Tai K, Gore M. Use of potentially inappropriate pain-related medications in elderly patients with painful neuropathic disorders. Journal of Neurology. 2006;253(Suppl 2):II/48, P190.
  25. Leslie D, Dukes E, Rowbotham D, Sadosky A, Tai K, Gore M. Use of amitriptyline in patients with painful neuropathic disorders in general practice settings in the United Kingdom. Journal of Neurology. 2006;253(Suppl 2):II/49, P191.
  26. Brandenburg N, Gore M, Zelman D. Sleep impairment in patients with painful diabetic peripheral neuropathy. Eighth International Conference on the Mechanisms and Treatment of Neuropathic Pain. November 2005.
  27. Gore M, Sadosky A, Rowbotham D, Tai K-S, Leslie D. Clinical characteristics and pain management in patients with painful diabetic neuropathy (PDN): a study using the UK General Practice Research Database (GPRD). 11th World Congress on Pain. August 2005.
  28. Gore M, Brandenburg NA, Tai KS. Burden of illness in painful diabetic peripheral neuropathy (DPN): The patients’ perspectives. 57th Annual Meeting of the American Academy of Neurology. April 2005.
  29. Gore M, Dukes E, Rowbotham D, Tai K-S, Leslie D. Use of amitriptyline in patients with painful neuropathic disorders in general practice settings in the United Kingdom. EU J Neurology. 2005;Vol 12(Suppl 2):74. Abstract # 1143.
  30. Gore M, Dukes E, Rowbotham D, Tai K-S, Leslie D, Sadosky A. Use of potentially inappropriate pain-related medications in elderly patients with painful neuropathic disorders (PNDs): a study using the UK general practice research database (GPRD). EU J Neurology. 2005;Vol 12(Suppl 2):74. Abstract # 1144.
  31. Gore M, Sadosky A, Rowbotham D, Tai K-S, Leslie D. Clinical characteristics and pain management in patients with painful diabetic neuropathy (PDN): a study using the UD general practice research database (GPRD). 11th World Congress on Pain. International Association for the Study of Pain. 2005. IASP Press. Page 365. Abstract # 1038-P280.
  32. Dukes E, Gore M, Leslie D, Tai K-S, Rowbotham D. Clinical characteristics and pain management in patients with painful diabetic neuropathy (PDN) in general practice settings in the UK [abstract]. Diabetologia. 2005;48(suppl 1);A350-A351. Abstract 964.
  33. Zelman D, Gore M, Brandenburg NA. Sleep impairment in patients with painful diabetic peripheral neuropathy. J Pain. 2005 b;6(3):S29.
  34. Gore M, Brandenburg NA, Tai K. Burden of illness in painful diabetic peripheral neuropathy (DPN): The patients’ perspectives. J Pain. 2005b;6(3):S28.
  35. Gore M, Brandenburg NA, Dukes E, Hoffman D, Snyder A, Tai K. Pain Severity in diabetic peripheral neuropathy: impact on patient functioning, medication use, and satisfaction with pain management. 7th Annual Meeting of the International Conference on the Mechanisms and Treatment of Neuropathic Pain. November 2004.
  36. Gore M, Sadosky A, Rowbotham D, Tai K-S, Leslie D. Clinical characteristics and pain management in patients with painful diabetic neuropathy (PDN): a study using the UK General Practice Research Database (GPRD). 12th Annual Meeting of the International Congress of Endocrinology (ICE). August 2004.
  37. Gore M, Brandenburg NA, Tai K, Freeman R. A survey of pain medication use among patients with painful diabetic peripheral neuropathy. 64th Annual Meeting of the American Diabetes Association. June 2004.
  38. Gore M, Brandenburg NA, Dukes E, Hoffman D, Snyder A, Tai K. Pain Severity in Diabetic Peripheral Neuropathy (DPN) affects Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. 64th Annual Meeting of the American Diabetes Association. June 2004.
  39. Gore M, Brandenburg NA, Dukes E, Hoffman D, Snyder A, Tai K. Pain Severity affects Patient Functioning, Symptoms of Anxiety and Depression, and Sleep in Patients with Painful DPN. International Congress of NeuPSIG on Neuropathic Pain—Changing Paradigms in Diagnosis and Treatment. May 2004.
  40. Gore M, Brandenburg NA, Dukes E, Hoffman D, Snyder A, Tai K. Pain Severity in Diabetic Peripheral Neuropathy (DPN) affects Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. The Journal of Pain. 2004;5(3)Suppl. 1:112. Abstract #1014.
  41. Gore M, Dukes E, Rowbotham D, Tai K-S, Leslie D. Clinical characteristics and pain management among patients with PNDs in general practice settings in the UK. European Journal of Neurology. Sept. 2004. Vol 11. Suppl. 2. Pg. 141.
  42. Zelman DC, Dukes E, Brandenburg NA, Bostrom A, Gore M. Classification of Mild, Moderate and Severe Pain Due to Diabetic Peripheral Neuropathy Based on Levels of Functional Disability. The Journal of Pain. 2004;5(3). Suppl. 1:114. #1025.
  43. Zelman DC, Gore M, Dukes E, Tai K, Brandenburg NA. Initial validation of a Modified Brief Pain Inventory for painful diabetic peripheral neuropathy (m-BPI-DPN). The Journal of Pain. 2004;5(3). Suppl. 1:112. #1016.
  44. Gore M, Brandenburg NA, Hoffman D, Tai KS. Pain Severity Affects Perceived Health Status in Patients with Diabetic Peripheral Neuropathy. Value in Health. 2004;7:3. #PDB25.
  45. Gore M, Frech F, Nguyen A, Tai KS, Shetzline MA. Development of a New Symptom-based Algorithm for Classifying IBS Patients into IBS Subgroups. Am J Gastroenterol. 2003;98:S219. Abstract # 663.
  46. Gore M, Frech F, Tai KS, Nguyen A, Shetzline MA. Burden of Illness in Patients with Irritable Bowel Syndrome with Constipation. Am J Gastroenterol. 2003;98:S219. Abstract # 662.
  47. Lennox RD, Fowler I, Gore M, Jones KC, Pethick N, O’Dowd L. Psychometric Validation of a Patient-based Preference Instrument: The Sensory Perceptions Questionnaire. American Academy of Allergy, Asthma, and Immunology Annual Meeting. March 2003.
  48. Gore M, Frech F, Yokoyama K, Tai K. Symptom Burden and Management of Irritable Bowel Syndrome: A Patient Perspective. Am J Gastroenterol. 2002;97:S239-S240. Abstract # 731.
  49. Gore M, Frech F, Tai, Yokoyama K. Management of Irritable Bowel Syndrome: The Patient’s Perspective. ACG 67th Annual Meeting. 2002.
  50. Becker RV, Noe L, Gore M, Kaneko K, Kato S, Shimozuma K, Watanabe T. The Methodology and Design of Evidence-based Disease Models Illustrated by a Breast Cancer Treatment Model for Japan. European ISPOR Annual Meeting. November 2001.
  51. Becker RV, Noe L, Gore M, Chen DM, Kaneko K, Kato S, Shimozuma K, Watanabe T. Using Level of Evidence Criteria in the Evaluation of Pharmacoeconomic Results. Value Health. 2001 Nov-Dec;4(6):432 (Abs.).
  52. Becker RV, Noe L, Gore M, Chen DM, Kaneko K, Kato S, Shimozuma K, Watanabe T. Incorporating Clinical Level of Evidence Criteria into a Breast Cancer Treatment Model for Japan. Value Health. 2001 Nov-Dec;4(6):421 (Abs.).
  53. Noe LL, Becker RV, Gore M, Martino S, Eiermann W, Namer M, Howell T, Bianco AR, Watanabe T, Chen DM. Disease Modeling: Developing the Infrastructure for a Comprehensive Multi-national, Clinical and Economic Breast Cancer Treatment Model. Value Health. 2001;4(2):93 (Abs.).
  54. Noe LL, Becker RV, Gore M, Martino S, Eiermann W, Namer M, Howell T, Bianco AR, Watanabe T, Chen DM. A New Approach to Disease Modeling with Numerous Comparators and Multiple Decision Trees: A Contributed Workshop. ISPOR 6th Annual International Meeting.
  55. Noe LL, Becker RV, Gore M, Martino S, Eiermann W, Namer M, Howell T, Bianco AR, Watanabe T, Chen DM. An Approach to Designing a Multi-national Model for the Current Treatment of Breast Cancer. European ISPOR Annual Meeting.
  56. Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP. The Cost-effectiveness of Tamoxifen in Reducing the Incidence of Breast Cancer. ASCO Annual Meeting. 1999.
  57. Noe LL, Vreland MG, Gore M, Trotter JP. Initial, Maintenance, and Terminal Costs of Care for Breast Cancer Patients. ISPOR Annual Meeting. 1999.
  58. Martin ML, Bushnell DM, Gore M. A Seven-day Voiding Diary for Urinary Incontinence. ISOQOL Annual Meeting 1999.
  59. Bushnell DM, Martin ML, Patrick D, Andrejasich C, Gore M. Development of an Individually Defined Activities Limitations Scale for UI. DIA Annual Meeting 1999.
  60. Noe LL, Becker RV, Gradishar WJ, Gore M, Trotter JP. The Cost-effectiveness of Tamoxifen in Prevention of Breast Cancer. Am J Manag Care. 1999;5(6):S389-406.
  61. Martin CG, Elting LS, Gore M, Rubenstein EB. What is a clinically significant Quality of Life difference in patients experiencing chemotherapy induced nausea and emesis? Antiemetics and Cancer Therapy Session, Multi-national Association for Supportive Care and Cancer Annual Meeting 1997.
  62. Frech F, Gore M. Legislation and its impact on community pharmacy. AAFP Meeting 1996.
  63. Gore M. Designing a Health Economics Assessment for Anzemet®, A New 5-HT3 Antagonist for Prevention and Treatment of Postoperative Nausea and Vomiting. Health Economics Symposia, AAFP Meeting 1996.
  64. Gore M, Namjoshi M. Developing an Instrument to Assess Quality of Life in HIV-related Disease, Health Economics Symposia, AAFP Meeting 1996.
  65. Gore M, Thomas J. Use and influence of Pharmacoeconomic Information in Decision Making in Hospitals. Clinical Therapeutics. Jan. 1,1996;Volume 18.

Avalon Personnel Have Served as Peer Reviewers of the Following Journals

  • American Journal of Hospital Pharmacy
  • American Journal of Pharmaceutical Education
  • Annals of the Rheumatic Diseases
  • Clinical Drug Investigation
  • Hemophilia
  • ISPOR Meeting Abstracts
  • Journal of Diabetes and Its Complications
  • Journal of Medical Economics
  • Journal of Pharmaceutical Marketing and Management
  • Journal of Research in Pharmaceutical Economics
  • Journal of Rheumatology
  • Journal of Social & Administrative Pharmacy
  • The American Journal of Pharmacy Benefits
  • Value in Health
CLICK TO PRINT THIS PAGE
Print Friendly, PDF & Email

Therapeutic Areas

  • Anti-infectives
  • CNS
  • CVS
  • Dermatology
  • Endocrine and Metabolic Disorders
  • GI Disorders
  • Oncology
  • Ophthalmology
  • Organ Transplant
  • Pain
  • Respiratory